Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    24138944 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Decitabine;   Drug: Rapamycin

Indicates status has not been verified in more than two years